Literature DB >> 31939370

Characterization of saliva in immunocompromised patients and tobacco users: A case-control study.

Abha Rani1, Mamatha Gowda Panchaksharappa1, Neetha Mellekatte Chandrashekarappa1, Rajeshwari G Annigeri1, Varsha Kanjani1.   

Abstract

OBJECTIVE: The aim of the study was to assess salivary flow rate, salivary pH, and salivary albumin concentration in systemically compromised subjects and tobacco users and its comparison to healthy controls.
MATERIALS AND METHODS: Sixty patients were selected and then were equally divided into systemically compromised group, tobacco users, and control group with 20 in each group. Saliva flow rate was assessed using modified Schirmer test (MST), salivary pH was estimated by pH meter, and salivary albumin concentration was determined using bromocresol green method.
RESULTS: The salivary flow rate readings measured by MST were 22.65 ± 2.79, 22.6 ± 3.57, and 33.22 ± 2.30 mm/3min in systemically compromised individuals, tobacco users, and control group, respectively (P < 0.001). The salivary pH was 6.80 ± 0.24, 6.81 ± 0.25, and 7.18 ± 0.17 in systemically compromised subjects, tobacco users, and control group, respectively (P < 0.001). The salivary albumin concentration was 2.49 ± 0.61, 0.73 ± 0.13, and 1.14 ± 0.12 g/dl in systemically compromised subjects, tobacco users, and control group, respectively (P < 0.001).
CONCLUSION: MST can be routinely used as chair-side investigation to evaluate salivary flow which is objective, inexpensive, easy-to-perform, and patient-friendly. The salivary flow rate, salivary pH, and salivary albumin level in systemically compromised subjects, tobacco users, and normal individuals showed significant differences.

Entities:  

Keywords:  Modified Schirmer test (MST); saliva; salivary albumin; salivary flow; salivary pH

Mesh:

Year:  2019        PMID: 31939370     DOI: 10.4103/ijdr.IJDR_642_18

Source DB:  PubMed          Journal:  Indian J Dent Res        ISSN: 0970-9290


  1 in total

1.  Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.

Authors:  Eiko Yamada; Ritsuo Takagi; Hiroshi Moro; Koji Sudo; Shingo Kato
Journal:  PLoS One       Date:  2021-02-18       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.